BioCentury
ARTICLE | Finance

One and done

NIH support for Syndax's HDAC inhibitor bolstered cancer play's B round

September 2, 2013 7:00 AM UTC

Syndax Pharmaceuticals Inc. plans to use its $26.6 million series B round to help fund a single Phase III trial of entinostat that it hopes will be sufficient for approval in breast cancer.

Existing investors Domain Associates, MPM Capital and Forward Ventures participated in last week's round along with new investor Rusnano...